Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by wexworthon Feb 02, 2021 12:43pm
223 Views
Post# 32447651

Rodan Launch date musings

Rodan Launch date musingsClinical study demonstrated two primary advantages of 1067 for the treatment of dyschromia (uneven skin tone/dark spots).

1. unlike hydroquinone containing products, Sirona's 1067 has the very specific clinical study proven advantage of targeting the dychromia and not the broader skin tone unique to the individual.

2. that Sirona's 1067 forumla is safe and cancer free

These are both game changers.

A couple of things that I am wondering about:

1. 2020 brought two big changes for the skin lightening market and reaffirmed for the world what is considered acceptable, socially and for human safety. What is the cosmetics industry response to both the BLM movement and widespread regulatory clamp down?

So far, many major cosmetics firms have pulled their hydronquinone containing products not just for safety and regulatory compliance but also in response to their obligation to do what is right.

There is a distinct difference between lightening your entire skin and just treating an annoying dark spot/aging spot. One is more and more seen as socially intolerant, the other is perfectly legitimate. Furthermore, Hydroquinone is akin to trying to surgically remove a problematic area with a hatchet, while Sirona's 1067 treatment would be akin to laser precision. 

If you want a legitimate treatment for a problematic area, you now require a doctors prescription for hydroquinone to treat dyschromia and you have to make sure you don't go "over the line" and inadvertently lighten the surrounding skin area. Nice, I replace my dark spot with a light and dark mess. And I get cancer. No thank you.

2. If one was going to go out with a leading position with this brand new product line, when would be the right time of the year which would resonate the best for brand awareness and a social campaign?

I am hoping this month or next, and it may be brilliant if it ends up being this month and the message is properly structured, but again, please caution as we have been completely off base two times before.

It has to come out some time, so the question is when?
<< Previous
Bullboard Posts
Next >>